As described previously (I. Kijima-Suda et al.,
Cancer Res., 46: 858-862, 1986), a
sialyltransferase inhibitor, 5-fluoro-2',3'-isopropylidene-5'-O-(4-N-acetyl-2,4-dideoxy-3,6,7,8-tetra -O- acetyl-1-methoxycarbonyl-D-glycero-alpha-D-galactooctapyranosyl)ur idine (KI-8110), inhibits pulmonary
metastasis of murine
colon adenocarcinoma 26 sublines of high (NL-17) and low (NL-44) metastatic potential. To investigate the mechanism of this inhibition, the effect of
KI-8110 on the metastatic cascade, especially on the interaction between
tumor cells and platelets which may play a crucial role in
tumor cell
metastasis, was examined. NL-17 cells induced irreversible platelet aggregation in heparinized human platelet-rich plasma in vitro. This activity was reduced by pretreatment of the
tumor cells with
KI-8110. Inhibition of aggregation was also induced by the treatment of
tumor cells with
neuraminidase or
Limax flavus agglutinin, a
lectin specific for
sialic acid.
Sialic acid,
fucose,
sialyllactose, and
bovine submaxillary mucin inhibited this
tumor cell-induced platelet aggregation, while
galactose,
mannose,
lactose,
alpha 1-acid glycoprotein,
fetuin, and asialo-
bovine submaxillary mucin did not.
KI-8110 also inhibited
platelet-derived growth factor-dependent growth of NL-17 cells, but showed no effect on
insulin or
epidermal growth factor-dependent growth of the
tumor cells.
Platelet-derived growth factor-induced phosphorylation of
membrane protein was reduced by treatment of NL-17 cells with
KI-8110. The same result was obtained in the
neuraminidase-treated membrane fraction of NL-17 cells. These results suggest that
KI-8110 inhibits experimental
tumor cell
metastasis by inhibiting the interaction between
tumor cells and host platelets in at least two pathways, and this may be due to a reduction of
sialic acid contents of the membrane surface of
tumor cells.